Keywords: Breast, Breast, gadopiclenol; MRI; breast
Motivation: Gadolinium dose reduction while maintaining MRI diagnostic efficacy is crucial.
Goal(s): Compare gadopiclenol (0.05 mmol/kg) and gadobutrol (0.1 mmol/kg) in breast MRI.
Approach: Post-hoc analysis on 70 patients with breast lesions from the PROMISE phase III study.
Lesion visualization was qualitatively (border delineation, internal morphology, contrast enhancement) and quantitatively (enhancement percentage [E%], lesion-to-background ratio [LBR]) evaluated by three blinded readers. Three additional readers assessed diagnostic preference.
Results: Gadopiclenol was non-inferior to gadobutrol for all qualitative visualization parameters.
E% was higher with gadopiclenol, while LBR was similar between the two GBCAs.
Readers had in most cases no preference between images with the two GBCAs.
Impact: Gadopiclenol at half the gadolinium dose compared to current GBCAs can be particularly beneficial in patients receiving multiple lifetime doses, such as high-risk women undergoing breast cancer screening.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords